Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of DKF-313 in Benign Prostatic Hyperplasia
NCT04947631Phase 3Completed
- Sponsor
- Dongkook Pharmaceutical
- Start
- Jul 2021
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dutasteride + tadalafil in benign prostatic hyperplasia (BPH) (3 arms), sponsored by Dongkook Pharmaceutical. Primary endpoint: Change in Total International Prostate Symptom Score at Week 48. Started Jul 2021; status: completed.
02
Drugs
dutasteride + tadalafil
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT04947631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04947631.